PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Budau, L.* ; Wilhelm, C.* ; Moll, R.* ; Jäkel, J.* ; Hirt, C.* ; Dölken, G.* ; Maschmeyer, G.* ; Neubauer, E.* ; Strauch, K. ; Burchert, A.* ; Herold, M.* ; Neubauer, A.*

Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: A secondary analysis of a randomized clinical trial.

J. Cancer Res. Clin. Oncol. 145, 2149-2156 (2019)
Verlagsversion Forschungsdaten DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
BackgroundFirst-line rituximab therapy together with chemotherapy is the standard care for patients with advanced follicular B-cell lymphoma, as rituximab together with chemotherapy prolongs progression-free and overall survival (Herold et al. 2007; Marcus et al. 2005). However, as not all patient subgroups benefit from combined immuno-chemotherapy, we asked whether the microenvironment may predict benefit from rituximab-based therapy.DesignTo address this question, we performed a retrospective immunohistochemical analysis on pathological specimens of 18 patients recruited into a randomized clinical trial, where patients with advanced follicular lymphoma were randomized into either chemotherapy or immuno-chemotherapy with rituximab (Herold et al. 2007).ResultsWe show here that rituximab exerts beneficial effects, especially in the subgroup of follicular lymphoma patients with low intrafollicular CD3, CD5, CD8, and ZAP70 and high CD56 and CD68 expression.ConclusionRituximab may overcome immune-dormancy in follicular lymphoma in cases with lower intrafollicular T-cell numbers and higher CD56 and CD68 cell counts. As this was a retrospective analysis on a small subgroup of patients, these data need to be corroborated in larger clinical trials.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
3.332
0.919
3
3
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Follicular Lymphoma ; Microenvironment ; Rituximab ; T Cells ; Nk Cells ; Macrophages; Tumor Microenvironment; Retrospective Analysis; 1st-line Mitoxantrone; Prognostic Value; Gene-expression; Survival; Transformation; Cyclophosphamide; Immunotherapy; Prednisolone
Sprache englisch
Veröffentlichungsjahr 2019
HGF-Berichtsjahr 2019
ISSN (print) / ISBN 0171-5216
e-ISSN 1432-1335
Zeitschrift Journal of Cancer Research and Clinical Oncology
Quellenangaben Band: 145, Heft: 8, Seiten: 2149-2156 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort 233 Spring St, New York, Ny 10013 Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Genetic Epidemiology (IGE)
POF Topic(s) 30501 - Systemic Analysis of Genetic and Environmental Factors that Impact Health
Forschungsfeld(er) Genetics and Epidemiology
PSP-Element(e) G-504100-001
DOI 10.1007/s00432-019-02961-9
WOS ID WOS:000477604700021
Scopus ID 85068864882
PubMed ID 31273513
Erfassungsdatum 2019-07-24
[➜Korrektur melden]